The efficacy results were interim and based on a relatively smaller set of participants, and the final efficacy will be determined only after the complete phase III trials results are announced. For the phase III trials, Pfizer and BioNTech have enrolled maximum 43,538 participants, followed by Gamalaya (40,000) and Moderna (30,000).